Please login to the form below
OncoVex
This page shows the latest OncoVex news and features for those working in and with pharma, biotech and healthcare.
AZ signs yet another cancer immunotherapy deal
The most advanced is Amgen's OncoVex (talimogene laherparepvec), which in 2013 became the first oncolytic virus to show efficacy in a phase III trial involving people with the skin cancer
Latest news
-
Amgen says viral melanoma therapy clears phase III trial
OncoVex demonstrates durable response in skin cancer patients. A novel therapy for skin cancer which makes use of the cell-killing activity of a virus has shown efficacy in a phase ... The melanoma immunotherapeutic - talimogene laherparepvec (also known
-
Disease focus: Melanoma
nilotinib. In development. Vaccines. OncoVEX GM-CSF. In development. Vaccines. MAGE-A3 ASCI.
-
Amgen to buy BioVex
BioVex's portfolio includes OncoVex (GM-CSF) – an investigational vaccine to treat melanoma and head and neck cancer. ... Philip Astley-Sparke, CEO, BioVex, also praised the agreement: "Amgen is ideally positioned to leverage the potential of OncoVEX
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Featured jobs
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Senior Medical Writer
-
Salary TBC
-
Medical Writer
-
Salary TBC
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Manager / Account Director
-
Competative
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Global Business Development Director – Health Education
-
excellent commission
-
Associate Director
-
£75, 000-90, 000
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Account Director, Medical Education
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Immunomedics craters after FDA rejects breast cancer ADC
- NHS England sees off AbbVie's Hep C legal challenge
- FDA expecting boom in cell and gene therapies
- Moving annual total (MAT)
- Novartis forges AI alliance with Oxford University
- A dynamic and challenging environment – what it’s like starting a career in MedComms
- UniQure cleared to start Huntington gene therapy trial
- HSJ Partnership Awards 2019 shortlist announced
- Unlocking the potential of science and technology in the UK
- A Magical Future – A year on from the graduate scheme
- Rising economic risk casts shadow on Davos meeting
PMHub
Havas Life Medicom
We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...
Latest intelligence
- Unlocking the potential of science and technology in the UK
- Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
- NHS regional footprints
- What to expect from 2019...
- Not another weight-loss ad
- Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
Quick links
Infographics
